GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ensysce Biosciences
Ensysce Biosciences is developing technology to create painkillers with overdose protection. Its stock price is a venture bet on solving the pressing opioid crisis. The chart reflects the binary risks of clinical trials.
Share prices of companies in the market segment - Narco farm
Ensysce Biosciences develops technologies to create safer opioid analgesics with protection against overdose and abuse. We've classified it as a "Narco-Pharma" company. The chart below shows how investors value companies fighting the opioid crisis.
Broad Market Index - GURU.Markets
Ensysce Biosciences is a biopharmaceutical company developing safer painkillers with overdose protection. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the pharmaceutical sector.
Change in the price of a company, segment, and market as a whole per day
ENSC - Daily change in the company's share price Ensysce Biosciences
Ensysce Biosciences, Inc.'s daily stock price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its overdose-protective painkillers.
Daily change in the price of a set of shares in a market segment - Narco farm
Ensysce Biosciences develops technologies to create safer opioid analgesics with overdose protection. This pharmaceutical segment is highly volatile and under close regulatory scrutiny. The chart below shows the average fluctuations in this niche, helping to assess the risks and potential of ENSC.
Daily change in the price of a broad market stock, index - GURU.Markets
Ensysce Biosciences develops painkillers with overdose protection. Given the severity of the opioid crisis, its developments are attracting attention. The company's shares are volatile and dependent on research progress, contributing to market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ensysce Biosciences
For Ensysce Biosciences, year-over-year performance is a story about developing safe opioids. Its 12-month market cap is entirely dependent on clinical trial data. The success of its overdose-prevention platforms could be a breakthrough in the fight against the opioid crisis and offer the market a highly sought-after solution.
Annual dynamics of market capitalization of the market segment - Narco farm
As an early-stage biotech, Ensysce is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its abuse-resistant painkillers. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ensysce Biosciences develops technologies to create safer opioid analgesics with overdose protection. Its year-over-year market capitalization reflects the severity of the opioid crisis and the hopes for a technological solution. The company's success could save thousands of lives and transform the pain relief market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ensysce Biosciences
Ensysce is a biopharmaceutical company developing safe opioids. Its monthly performance is entirely dependent on the results of its clinical trials. News of the progress of its unique overdose protection technology is the main catalyst.
Monthly dynamics of market capitalization of the market segment - Narco farm
Ensysce Biosciences is developing technologies to create safer opioid analgesics with protection against overdose and abuse. This is a response to the opioid crisis. The company's success depends on clinical success. The pharmaceutical sector's schedule will demonstrate the overall interest in this issue, which provides the backdrop for evaluating Ensysce's innovative approach.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ensysce Biosciences is developing an "overdose protection" technology for opioid analgesics. This is a socially significant innovation. The company's stock price is not dependent on the market, but is determined by clinical trial results and regulatory decisions. Success could lead to explosive growth due to the severity of the opioid crisis.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ensysce Biosciences
Ensysce Biosciences is developing an "overdose protection" technology for opioid analgesics, addressing a pressing social issue. Its weekly stock price is reflecting clinical trial data and FDA approval or rejection of this innovative approach.
Weekly dynamics of market capitalization of the market segment - Narco farm
Ensysce Biosciences is developing painkillers with overdose protection, attempting to address one of the most pressing healthcare challenges. This chart shows how investors view the potential of its technology and how its performance compares to other pharmaceutical companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Ensysce Biosciences develops painkillers with overdose protection. Its stock is a classic biotech whose performance depends on news about trials. The chart clearly demonstrates this disconnect from the broader market and its macroeconomic drivers.
Market capitalization of the company, segment and market as a whole
ENSC - Market capitalization of the company Ensysce Biosciences
Ensysce Biosciences' market capitalization chart reflects investors' bets on its technology to create safer opioid analgesics. Its performance reflects the market's belief that its overdose-protection drugs will solve one of the most pressing healthcare problems. Its low valuation reflects both its enormous potential and the high risk of clinical failure.
ENSC - Share of the company's market capitalization Ensysce Biosciences within the market segment - Narco farm
Ensysce Biosciences develops technologies to create "safe" opioids that are abuse-resistant. Its market share in the pharmaceutical sector is small, but it is solving a pressing social problem. Its capitalization is based on its TAAP and MPAR platforms, which can prevent overdoses.
Market capitalization of the market segment - Narco farm
This chart shows the total market capitalization of the entire legal cannabis and pharmaceutical sectors. For Ensysce Biosciences, which is developing "safe" opioids, this line is a map of the battle against addiction. Its dynamics indicate the willingness of investors to invest in technologies that promise to reduce the risks associated with powerful painkillers.
Market capitalization of all companies included in a broad market index - GURU.Markets
Ensysce Biosciences develops technologies to create safer, overdose-resistant opioid analgesics. Its market capitalization is based on its efforts to combat the opioid crisis. Its market share is determined by the search for less dangerous painkillers.
Book value capitalization of the company, segment and market as a whole
ENSC - Book value capitalization of the company Ensysce Biosciences
Ensysce Biosciences develops opioid overdose protection technology. Its book value represents its financial resources for R&D. This consists of cash that allows the company to conduct clinical trials of its innovative drugs. How has this capital changed? The chart below shows.
ENSC - Share of the company's book capitalization Ensysce Biosciences within the market segment - Narco farm
Ensysce Biosciences develops safer opioid analgesics. Its research requires a lab to support its patented overdose protection technologies. The chart shows the company's share of the physical R&D infrastructure dedicated to combating the opioid crisis.
Market segment balance sheet capitalization - Narco farm
Ensysce Biosciences is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Ensysce focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Ensysce Biosciences' assets are not factories, but patented technologies for creating opioid analgesics with overdose- and abuse-resistant properties. The book value reflects the capital invested in clinical trials of these safer painkillers.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ensysce Biosciences
Ensysce Biosciences is developing safer opioid analgesics with overdose protection. Its market capitalization reflects its potential to solve one of the most pressing healthcare problems. This is a bet on its unique chemical technology.
Market to book capitalization ratio in a market segment - Narco farm
Ensysce Biosciences is developing technology to create safer opioid analgesics. This is a socially significant task. The chart shows how investors assess its potential to solve the problem of opioid addiction, betting on its scientific developments.
Market to book capitalization ratio for the market as a whole
Ensysce Biosciences develops safer opioid analgesics to reduce the risk of abuse. The company's market value is a bet on its ability to solve a serious social problem. This chart shows the premium investors place on high-impact technologies in the pharmaceutical industry.
Debts of the company, segment and market as a whole
ENSC - Company debts Ensysce Biosciences
Ensysce Biosciences develops technologies to create safer opioid analgesics. As a clinical-stage company, it relies entirely on external funding. This chart shows how it raises capital to conduct expensive clinical trials of its innovative but risky technology.
Market segment debts - Narco farm
Ensysce Biosciences develops technologies to create safer opioid analgesics with protection against overdose and abuse. This chart shows how the biopharmaceutical company is funding its clinical trials in an effort to address the serious opioid crisis, which requires overcoming complex regulatory hurdles.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ensysce Biosciences
Ensysce Biosciences is developing overdose protection technology for opioid analgesics. Clinical trials of such drugs with enhanced safety are a lengthy and expensive process. This chart shows how the company uses debt to finance its high-risk but socially significant pharmaceutical developments.
Market segment debt to market segment book capitalization - Narco farm
Ensysce Biosciences develops technologies to create safer opioid analgesics with overdose protection. This is an important social and medical goal. This chart shows how the company finances its R&D. It relates its debt structure to the overall financial landscape of the biotech sector.
Debt to book value of all companies in the market
Ensysce Biosciences develops technologies to create safer opioid analgesics with overdose protection. This is a socially important but complex area of pharmaceuticals. How dependent is the company on debt for its research? This graph of total debt in the economy allows us to assess the riskiness of its financial model.
P/E of the company, segment and market as a whole
P/E - Ensysce Biosciences
Ensysce Biosciences is developing safer painkillers with overdose protection. This chart shows how investors view its technology amid the opioid crisis. The valuation is heavily dependent on clinical trial results and potential regulatory approval.
P/E of the market segment - Narco farm
Ensysce Biosciences is a biopharmaceutical company developing safer opioid analgesics using technologies that prevent overdose and abuse. This chart illustrates the average valuation in the pharmaceutical sector, where investors perceive a huge need to address the opioid crisis, but also high development risks.
P/E of the market as a whole
Ensysce Biosciences is a biopharmaceutical company developing safer opioid analgesics using technologies that prevent overdose and abuse. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether ENSC's valuation is based on faith in its unique approach to solving the opioid crisis or is moving in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ensysce Biosciences
Ensysce Biosciences is developing a technology to create opioid analgesics with overdose and abuse protection. This could be the solution to the opioid crisis. This chart reflects investor confidence in the potential of this technology and its ability to transform the pain medication market, which shapes future revenue expectations.
%20P%2FE%20Ensysce%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ensysce-Biosciences&v=1772599161518 "Chart of the company's future (projected) P/E Ensysce Biosciences")
Future (projected) P/E of the market segment - Narco farm
Ensysce Biosciences develops safer opioid analgesics using technologies that prevent overdose and abuse. The chart shows average profitability expectations in the sector, helping to understand the market's confidence in the company's ability to solve the pressing opioid crisis.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Narco-farm&v=1772599161602 "Future (projected) P/E graph of the market segment - Narco farm")
Future (projected) P/E of the market as a whole
Ensysce Biosciences is developing painkillers with overdose and abuse protection. This is a technological approach to solving the pressing problem of the opioid crisis. This market sentiment chart reflects the investor willingness to invest in innovative addiction treatment solutions that require complex clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772599161665 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ensysce Biosciences
Ensysce Biosciences develops technologies to create safer opioid analgesics with protection against overdose and abuse. Financial indicators reflect R&D expenditures. This chart shows investments in addressing a serious social and medical problem—the opioid crisis.
Profit of companies in the market segment - Narco farm
Ensysce Biosciences is developing safer opioid analgesics using technologies that prevent overdose and abuse. This is a response to the opioid crisis. This chart shows the overall profitability of the addiction treatment sector, where creating effective but non-addictive painkillers is one of the pharmaceutical industry's most important goals.
Overall market profit
Ensysce Biosciences develops technologies to create safer opioid analgesics with overdose protection. The need to address the opioid crisis is enormous and unaffected by the state of the economy. The company's success is determined by clinical trial results and regulatory approvals, not by the macroeconomic trends visible in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ensysce Biosciences
Ensysce Biosciences is developing technology to create opioid analgesics with overdose and abuse protection. Future profits depend on the success of this technology in combating the opioid crisis. This chart reflects analysts' hopes that the company will be able to offer safer painkillers.
%20profit%20of%20the%20company%20Ensysce%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ensysce-Biosciences&v=1772599161799 "Graph of future (projected) profit of the company Ensysce Biosciences")
Future (predicted) profit of companies in the market segment - Narco farm
Ensysce Biosciences is developing technologies to create safer opioid analgesics with protection against overdose and abuse. This could be a key solution in the fight against the opioid crisis. This chart shows revenue projections for the pharmaceutical sector, providing context for assessing the potential of Ensysce's technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Narco-farm&v=1772599161809 "Graph of future (predicted) profits of companies in a market segment - Narco farm")
Future (predicted) profit of the market as a whole
Ensysce Biosciences is developing safer opioid analgesics to prevent overdoses. Its future depends on the success of clinical trials and regulatory approval. This economic outlook affects the overall investment climate in the biotech sector, which underpins the funding of such companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772599161842 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ensysce Biosciences
Ensysce Biosciences is developing painkillers with overdose protection. There is no revenue at the clinical stage. This chart reflects investor hopes that the company will offer a safer alternative to traditional opioids and address a pressing social problem.
P/S market segment - Narco farm
Ensysce Biosciences is developing a new generation of painkillers with overdose and abuse protection. Their TAAP and MPAR technologies aim to address the acute opioid crisis by making analgesics safer. This chart shows the average revenue estimate for the sector, helping to assess the potential of this socially significant innovation.
P/S of the market as a whole
Ensysce Biosciences develops technologies to create safer opioid analgesics that protect against overdose. This chart highlights that the valuation of such companies is based on their ability to solve a pressing social and medical problem, which can lead to high valuations even at an early stage.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ensysce Biosciences
Ensysce Biosciences is developing safer opioid analgesics with protection against overdose and abuse. For such a company, valuing its future revenue is crucial. It reflects investors' hopes that its drugs will help combat the opioid crisis by offering effective pain relief without the associated risks, creating a significant market for them.
%20P%2FS%20Ensysce%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ensysce-Biosciences&v=1772599161937 "The graph of the company's future (projected) P/S Ensysce Biosciences")
Future (projected) P/S of the market segment - Narco farm
Ensysce Biosciences develops technologies to create safer opioid analgesics with protection against overdose and abuse. This chart compares the company's estimated future sales with industry expectations. It shows how investors view its potential to address the pressing opioid crisis and the commercial prospects of its drug candidates.
%20P%2FS%20market%20segment%20graph%20-%20Narco%20farm&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Narco-farm&v=1772599161952 "Future (projected) P/S market segment graph - Narco farm")
Future (projected) P/S of the market as a whole
Ensysce Biosciences develops technologies to create painkillers with overdose- and abuse-resistant properties. The company's future depends on the clinical success of its TAAP and MPAR platforms. This market outlook chart reflects investor hopes for a technological solution to the acute opioid crisis.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772599161976 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ensysce Biosciences
This metric reflects Ensysce Biosciences, a biopharmaceutical company, its financial performance. The company develops opioid analgesics with overdose and abuse protection. Being in clinical trials, it has no commercial sales revenue.
Sales of companies in the market segment - Narco farm
Ensysce Biosciences is developing a new generation of painkillers with overdose protection. Currently in the clinical stage, the company has no sales revenue yet. Its future revenue will depend on the success of its unique technology in addressing the acute opioid crisis.
Overall market sales
Ensysce Biosciences develops technologies to create safer opioid analgesics with overdose protection. The company is addressing the pressing issue of the opioid crisis. This general economics chart is irrelevant to the company's mission: saving lives by offering innovative pain relief solutions.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ensysce Biosciences
Ensysce Biosciences develops technologies to create safer opioid analgesics with protection against overdose and abuse. Future revenue depends on the success of clinical trials and the commercialization of its platform. This chart reflects analyst expectations for potential demand for safer painkillers amid the opioid crisis.
%20sales%20of%20the%20company%20Ensysce%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ensysce-Biosciences&v=1772599162148 "Schedule of future (projected) sales of the company Ensysce Biosciences")
Future (projected) sales of companies in the market segment - Narco farm
Ensysce Biosciences develops technologies to create opioid analgesics with overdose and abuse protection. This chart shows the forecast for the pharmaceutical market. Is there a pressing need for safer painkillers that could drive growth in this segment? This reflects general expectations.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Narco-farm&v=1772599162222 "Schedule of future (projected) sales of companies in the market segment - Narco farm")
Future (projected) sales of the market as a whole
Ensysce Biosciences develops technologies to create safer opioid analgesics with overdose protection. The company's success depends on clinical trials and addressing the acute opioid crisis. This general economic activity chart has no bearing on this critical healthcare need or Ensysce's scientific developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772599162238 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ensysce Biosciences
Ensysce Biosciences develops technologies to create safer opioid analgesics with overdose protection. This chart shows the financial trajectory of the company solving a serious healthcare problem. Profitability depends on the success of clinical trials and regulatory approval of its drugs, which could become safer alternatives to traditional opioids.
Market segment marginality - Narco farm
Ensysce Biosciences, Inc. is a biopharmaceutical company developing safer opioid analgesics with overdose protection. This chart reflects its financial performance at the clinical stage, where profitability depends on the success of its technology in addressing the acute opioid crisis and obtaining regulatory approval.
Market marginality as a whole
Ensysce Biosciences develops technologies to create safer opioid analgesics with overdose protection. The company aims to address a pressing public health need. This overall return chart reflects the investment climate that influences funding for projects aimed at combating the opioid crisis.
Employees in the company, segment and market as a whole
Number of employees in the company Ensysce Biosciences
Ensysce Biosciences develops technologies to create safer opioid analgesics with overdose protection. Its small team of scientists is its greatest asset. This chart shows how the biotech startup manages its resources during clinical trials as it works to address the pressing opioid crisis.
Share of the company's employees Ensysce Biosciences within the market segment - Narco farm
Ensysce Biosciences is developing a new generation of opioid analgesics with overdose and abuse protection. This is a challenging task for a team of pharmacological chemists and clinical trial specialists. This graph shows the company's market share, reflecting its scientific potential and the scale of its R&D activities in an important social and medical field.
Number of employees in the market segment - Narco farm
Ensysce Biosciences develops technologies to create safer opioid analgesics with protection against overdose and abuse. This chart shows employment in the addiction pharmaceuticals sector. The opioid crisis requires innovative solutions, and Ensysce's technologies can be part of the answer to this serious problem.
Number of employees in the market as a whole
Ensysce Biosciences is developing safer opioid analgesics to prevent overdoses. This is a socially significant innovation. The company's growth is driven not by economics, but by success in clinical trials. This chart shows general trends, but Ensysce represents a sector where job creation is directly linked to solving a pressing healthcare problem.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ensysce Biosciences (ENSC)
Ensysce Biosciences is a biotech company developing drugs (including opioids) with overdose and abuse protection (TAAP and MPAR platforms). This chart shows how the market values their IP. It reflects the market value per scientist, which is a bet on their unique drug delivery technology.
%20of%20the%20company%20Ensysce%20Biosciences%20(ENSC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ensysce-Biosciences-ENSC&v=1772599162517 "Chart of market capitalization per employee (in thousands of dollars) of the company Ensysce Biosciences (ENSC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Narco farm
Ensysce Biosciences (ENSC) develops technologies to create safer opioid analgesics with overdose protection. In the pharmaceutical industry, this metric reflects social impact and commercial potential. A very high valuation per employee may indicate that the company has found a solution to the opioid crisis, representing a multibillion-dollar opportunity.
%20by%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Narco-farm&v=1772599162622 "Market capitalization per employee (in thousands of dollars) by market segment - Narco farm")
Market capitalization per employee (in thousands of dollars) for the overall market
Ensysce Biosciences is developing safer opioid analgesics with overdose protection. Its pricing is based on the potential of this technology. The chart shows a high valuation per employee, as the opioid crisis is a huge problem, and the company's solution could have enormous social and commercial impact.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772599162681 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ensysce Biosciences (ENSC)
Ensysce Biosciences is a biotech company developing "safe" opioids (with overdose protection). It is a clinical-stage R&D company. This chart shows the R&D workload. The negative figure (loss per employee) reflects how much capital the company is investing in each scientist to develop this important technology.
%20Chart%20Ensysce%20Biosciences%20(ENSC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ensysce-Biosciences-ENSC&v=1772599162732 "Company Profit Per Employee (in thousands of dollars) Chart Ensysce Biosciences (ENSC)")
Profit per employee (in thousands of dollars) in the market segment - Narco farm
Ensysce Biosciences, Inc. develops technologies to create safer opioid analgesics with overdose protection. In the pharmaceutical industry, which addresses pressing social issues, team efficiency is paramount. This chart reflects the financial return per employee, which is an indicator of progress toward the development of breakthrough and safe medications.
%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Narco-farm&v=1772599162760 "Chart of profit per employee (in thousands of dollars) in the market segment - Narco farm")
Profit per employee (in thousands of dollars) for the market as a whole
Ensysce Biosciences is a biotech company developing "safe" opioids. Their technologies (TAAP, MPAR) are designed to prevent overdose and abuse. It's an R&D company. This chart, showing average profitability, helps to understand the contrast with biotech, where a team of scientists burns through capital in hopes of drug approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772599162763 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ensysce Biosciences (ENSC)
Ensysce Biosciences is developing safer opioid analgesics to prevent overdoses. At the clinical stage, this rate is minimal. This reflects enormous social and commercial potential: a successful product could capture significant market share and lead to explosive growth.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ensysce-Biosciences-ENSC&v=1772599162784 "Sales chart per company employee Ensysce Biosciences (ENSC)")
Sales per employee in the market segment - Narco farm
Ensysce Biosciences is a clinical-stage biotech developing "safe" opioids (with overdose protection, TAAP) and ADHD medications. They have no commercial revenue. This chart, showing the average output in the sector, serves as a barometer of ENSC's R&D staff burn rate.
Sales per employee for the market as a whole
Ensysce Biosciences is a biotech company developing overdose-protection drugs, specifically "safe" opioids. Their business is R&D. This chart reflects their clinical stage: the company is investing in research and does not yet have commercial revenue from sales.
Short shares by company, segment and market as a whole
Shares shorted by company Ensysce Biosciences (ENSC)
Ensysce Biosciences (ENSC) is developing opioids (painkillers) with overdose- and abuse-resistant features. This chart shows the number of short positions. Short sellers may doubt the company's technology actually works or that it will pass the FDA's rigorous regulatory review for opioids.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ensysce-Biosciences-ENSC&v=1772599162806 "Short Shares Chart for the Company Ensysce Biosciences (ENSC)")
Shares shorted by market segment - Narco farm
Ensysce Biosciences (ENSC) is a pharmaceutical company developing opioids with abuse- and overdose-protection properties (TRYP and MPAR technologies). This chart aggregates short positions across the biotech sector. It reflects investor skepticism about opioid development, given the legal and regulatory risks.
Shares shorted by the overall market
Ensysce Biosciences is developing "safe" opioids (overdose protection). This chart illustrates the overall market pessimism. Investors see significant R&D and regulatory risk here. In times of fear, the market is unwilling to bet on the company's ability to secure FDA approval for such a complex and "toxic" topic as opioids.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ensysce Biosciences (ENSC)
Ensysce Biosciences is developing a technology for "safe" opioids that are abuse-resistant. It's a response to the opioid crisis. This chart represents the FDA approval "pulse." Investor interest "overheats" on any positive news about clinical trials of their unique technology.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ensysce-Biosciences-ENSC&v=1772599163129 "RSI 14 indicator chart for the company's stock Ensysce Biosciences (ENSC)")
RSI 14 Market Segment - Narco farm
Ensysce (ENSC) is a biotech company trying to solve the opioid crisis. They are developing "smart" painkillers (TAAPs) that shut off in the event of an overdose. This chart tracks overall sentiment in the Pharma/Cannabis sector. It helps investors understand whether ENSC's performance reflects their technology or whether the overall industry is overheated or oversold.
RSI 14 for the overall market
For Ensysce Biosciences, a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ENSC (Ensysce Biosciences)
Ensysce Biosciences is developing a new generation of "safe" opioids. Their drugs (PF614) are designed with abuse-deterrent and overdose-preventing technology. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ENSC-Ensysce-Biosciences&v=1772599163293 "A chart showing analyst consensus forecasts for the expected stock price. ENSC (Ensysce Biosciences)")
The difference between the consensus estimate and the actual stock price ENSC (Ensysce Biosciences)
Ensysce is a biotech company solving the opioid crisis. It creates "smart" painkillers (TAAP platform) that are abuse- and overdose-resistant. This chart shows how much the current stock price differs from the "fair" value predicted by analysts. It reflects their faith in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ENSC-Ensysce-Biosciences&v=1772599163327 "A chart showing the difference between the consensus forecast and the actual stock price. ENSC (Ensysce Biosciences)")
Analyst consensus forecast for stock prices by market segment - Narco farm
Ensysce (ENSC) is a biotech company developing "safe" opioids (PF614) with overdose- and abuse-protection technology. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe in the need for "safe" opioids amid the opioid crisis.
Analysts' consensus forecast for the overall market share price
Ensysce Biosciences is a biotech company developing "safe" opioids: medications (TAFs) with overdose and abuse protection. This chart reflects the overall "risk appetite" in the market. For Ensysce, which operates in a complex and highly regulated field (pain treatment), overall optimism is important, but their success depends more on regulatory approval (FDA).
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ensysce Biosciences
Ensysce Biosciences is an R&D company working on safe opioids. Their signature feature is their two R&D platforms: overdose prevention (TAAP) and abuse prevention (MPAR). They're a chemical lock for painkillers. This chart is a clear indicator of faith in their R&D. It reflects their (very risky) pipeline and their chances of FDA approval in this politically charged niche.
AKIMA Market Segment Index - Narco farm
Ensysce Biosciences (ENSC) is solving the opioid crisis through chemistry. The company develops smart painkillers (TAAP and PF614 platforms) that are activated only when administered correctly (orally) and inhibited if abused (e.g., through injection). This chart shows the average index for the segment, helping to assess how this technology compares to the industry average.
The AKIM Index for the overall market
Ensysce Biosciences is a biotech company developing abuse-resistant opioids (activated only in the stomach) for pain treatment. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is solving the opioid crisis through chemistry, compares to overall economic trends.
